Ameliorative effects of Gualou Guizhi decoction on inflammation in focal cerebral ischemic-reperfusion injury

Zhang,Yuqin; Zhang,Shengnan; Li,Huang; Huang,Mei; Xu,Wei; Chu,Kedan; Chen,Lidian; Chen,Xianwen

doi:10.3892/mmr.2015.3515

Ameliorative effects of Gualou Guizhi decoction on inflammation in focal cerebral ischemic-reperfusion injury

Authors:
- Yuqin Zhang
- Shengnan Zhang
- Huang Li
- Mei Huang
- Wei Xu
- Kedan Chu
- Lidian Chen
- Xianwen Chen
View Affiliations

Affiliations: College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: March 19, 2015 https://doi.org/10.3892/mmr.2015.3515
Pages: 988-994
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gualou Guizhi decoction (GLGZD) is a well-established Traditional Chinese Medicinal formulation which has long been used to treat stroke in a clinical setting in China. The present study investigated the ameliorative effects of GLGZD on inflammation in focal cerebral ischemic‑reperfusion injury. A rat model of middle cerebral artery occlusion (MCAO) was employed. Rats were administrated GLGZD (7.2 and 14.4 g/kg per day) or saline as control 2 h after reperfusion and daily over the following seven days. Neurological deﬁcit score and screen test were evaluated at 1, 3, 5 and 7 days after MCAO. Brain infarct size and brain histological changes were observed via 2,3,5‑triphenyltetrazolium chloride staining and regular hematoxylin & eosin staining. Furthermore, inflammation mediators and nuclear factor‑κB (NF‑κB) were investigated using ELISA and immunohistochemistry. GLGZD treatment significantly improved neurological function, ameliorated histological changes to the brain and decreased infarct size in focal cerebral ischemic‑reperfusion injury. GLGZD was found to significantly reduce interleukin (IL)‑1, tumor necrosis factor‑α and NF‑κB levels, while increasing levels of IL‑10. In conclusion, the present study suggested that GLGZD has a neuroprotective effect on focal cerebral ischemic‑reperfusion injury and this effect is likely to be associated with the anti-inflammatory function of GLGZD.

View Figures

View References

1	Donnan GA, Fisher M, Macleod M and Davis SM: Stroke. Lancet. 371:1612–1623. 2008. View Article : Google Scholar : PubMed/NCBI
2	Huang J, Upadhyay UM and Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 66:232–245. 2006. View Article : Google Scholar : PubMed/NCBI
3	Klijn CJ and Hankey GJ: Management of acute ischaemic stroke: new guidelines from the American stroke association and European stroke initiative. Lancet Neurol. 2:698–701. 2003. View Article : Google Scholar : PubMed/NCBI
4	Wu ZS, Yao CH and Zhao D: China’s population of stroke morbidity, mortality, epidemiological studies. Chin J Epidemiology. 24:236–239. 2003.
5	Brouns R and De Deyn PP: The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 111:483–495. 2009. View Article : Google Scholar : PubMed/NCBI
6	Amantea D, Nappi G, Bernardi G, Bagetta G and Corasaniti MT: Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 276:13–26. 2009. View Article : Google Scholar
7	Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A and Licata G: Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des. 14:3574–3589. 2008. View Article : Google Scholar : PubMed/NCBI
8	Terao S, Yilmaz G, Stokes KY, Ishikawa M, Kawase T and Granger DN: Inflammatory and injury responses to ischemic stroke in obese mice. Stroke. 39:943–950. 2008. View Article : Google Scholar : PubMed/NCBI
9	Dirnagl U, Iadecola C and Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:391–397. 1999. View Article : Google Scholar : PubMed/NCBI
10	Son HY, Han HS, Jung HW and Park YK: Panax notoginseng attenuates the infarct volume in rat ischemic brain and the inflammatory response of microglia. J Pharmacol Sci. 109:368–379. 2009. View Article : Google Scholar : PubMed/NCBI
11	Han HS and Yenari MA: Cellular targets of brain inflammation in stroke. Curr Opin Investig Drugs. 4:522–529. 2003.PubMed/NCBI
12	Allan SM and Rothwell NJ: Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2:734–744. 2001. View Article : Google Scholar : PubMed/NCBI
13	Qing Wang, Xian Nan Tang and Yenari Midori A: The inflammatory response in stroke. J Neuroimmuno. 1184:53–68. 2007.
14	Yang GY, Gong C, Qin Z, Ye W, Mao Y and Bertz AL: Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuro Report. 9:2131–2134. 1998.
15	Guo RB, Wang GF, Zhao AP, Gu J, Sun XL and Hu G: Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses. PLoS One. 7:e497012012. View Article : Google Scholar
16	Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S and Tarkowski A: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 26:1393–1398. 1995. View Article : Google Scholar : PubMed/NCBI
17	Camarata PJ, Heros RC and Latchaw RE: ‘Brain attack’: the rationale for treating stroke as a medical emergency. Neurosurgery. 34:144–157. 1994. View Article : Google Scholar
18	Ringleb PA, Schellinger PD, Schranz C and Hacke W: Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke : useful or harmful? Stroke. 33:1437–1441. 2002. View Article : Google Scholar : PubMed/NCBI
19	Tao BH, Yang H, Xu ZX and Liu SY: Effect and safety of combined therapy of defibringen, anticoagulation and anti-plateletget for progressivity stroke. Chinese General Practice. 11:2134–2136. 2008.
20	Camerlingo M, Salvi P, Belloni G, Cesana BM and Mamoli A: Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 36:2415–2420. 2005. View Article : Google Scholar : PubMed/NCBI
21	Wang W, Ying WB, Bo JL, Wu T and Ding XS: Edaravone clinical safety evaluation. Chinese J Neurology. 42:486–489. 2009.
22	Shuaib A, Lees KR, Lyden P, et al: Emeribe U., SAINT II Trial Investigators: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 357:1562–1571. 2007. View Article : Google Scholar
23	Cho HJ and Kim YJ: Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 31:171–176. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sun X: Research on formula treating paralysis and spasticity from ‘treatise on febrile and miscellaneous diseases’. Chinese Journal of Basic Medicine In Traditional Chinese Medicine. 8:644–645. 2010.In Chinese.
25	Zhang L and Ai H: Effects of Gua Lou Gui Zhi decoction on c-fos and c-jun in epileptic rats. Journal of Sichuan of Traditional Chinese Medicine. 23:21–22. 2005.In Chinese.
26	Yang C, Chen L and Tao J: New usage of a classical formula-Gua Lou Gui Zhi decoction. Liaoning Journal of Traditional Chinese Medicine. 8:166–167. 2010.In Chinese.
27	Hu H, Li Z, Zhu X, et al: Gua Lou Gui Zhi decoction suppresses LPS-induced activation of the TLR4/NF-κB pathway in BV-2 murine microglial cells. Int J Mol Me. 31:1327–1332. 2013.
28	Huang J, Tao J, Xue XH, et al: Gua Lou Gui Zhi decoction exerts neuroprotective effects on post-stroke spasticity via the modulation of glutamate levels and AMPA receptor expression. Inter J Mol Med. 31:841–848. 2013.
29	Muir KW, Tyrrell P, Sattar N and Warburton E: Inflammation and ischaemic stroke. Curr Opin Neurol. 20:334–342. 2007. View Article : Google Scholar : PubMed/NCBI
30	Han HS and Yenari MA: Cellular targets of brain inflammation in stroke. Curr Opin Investig Drugs. 4:522–529. 2003.PubMed/NCBI
31	Wang ZQ, Wu DC, Huang FP and Yang GY: Inhibition of MEK/ERK 1 and 2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res. 996:55–66. 2004. View Article : Google Scholar
32	Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC and Feuerstein GZ: Tumor necrosis factor-alpha expression in ischemic neurons. Stroke. 25:1481–1488. 1994. View Article : Google Scholar : PubMed/NCBI
33	Gee JM, Kalil A, Shea C and Becker KJ: Lymphocytes: potential mediators of postischemic injuryand neuroprotection. Stroke. 38:783–788. 2007. View Article : Google Scholar : PubMed/NCBI
34	Wang XQ, Peng YP, Lu JH, Cao BB and Qiu YH: Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK. Neurosci Lett. 450:122–126. 2009. View Article : Google Scholar
35	Baeuerle PA and Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 12:141–179. 1994. View Article : Google Scholar : PubMed/NCBI
36	Berti R, Williams AJ, Moffett JR, et al: Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J Cereb Blood Flow Metab. 22:1068–1079. 2002. View Article : Google Scholar : PubMed/NCBI